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gests that though oncologists use economic tools in their
choice of therapy, the extent of use is lower than ex-
pected; and the choice of therapy varied more with the
first and third lines of therapy.
PCN5
COST-EFFECTIVENESS OF EARLY DETECTION 
AND PREVENTION OF COLORECTAL CANCER 
BY SCREENING WITH FECAL OCCULT
BLOOD TESTS
Parson RE, Baker JT
Beckman Coulter, Inc., Primary Care Diagnostics, Palo Alto, 
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Colorectal cancer (CRC), the second leading cause of
cancer deaths in the US, can be detected in its early
stages. Detection and removal of adenomas can prevent
CRC. Early detection of CRC by screening asymptomatic
populations with fecal occult blood tests (FOBTs) can
significantly reduce mortality and morbidity. OBJEC-
TIVE: The purpose of this analysis was to measure out-
comes when FOBTs are used as the primary screening
tools. METHODS: A cost-effectiveness model was devel-
oped for 10 years of annual serial screening. Assumptions
for the fixed cohort population were for an initial popu-
lation of 100,000 with 0.33% prevalence of CRC,
5.64% prevalence of adenomas (1 cm), 2.91% annual
conversion rate of adenomas to CRC, and an annual inci-
dence rate for adenomas of 0.31%. Two FOBTs were
evaluated in this analysis: Hemoccult (HO), and Hemoc-
cult SENSA (HOS). A decision-analytic model was used
to evaluate testing modalities, test positivity rates, pro-
gram compliance, treatment options and surveillance reg-
imens. Test performance statistics were obtained from
published clinical trials and related healthcare data. RE-
SULTS: Summary of Model Outcomes Compared to a
No Testing Scenario:
CONCLUSION: Cost-effective screening of asymptom-
atic populations can be achieved with either FOBT. HOS,
however, has better sensitivity than HO in detecting ade-
nomas and CRC. This results in greater prevention of
CRC and lower treatment and terminal care costs that fa-
vorably impact the $/LYG estimate.
FOBT
Adenomas
Detected
CRC
Prevented
CRC Deaths
Prevented
$ (000)/Life Year
Gained (LYG)
HO 2,016 304 193 $32
HOS 3,439 603 303 $25
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Hereditary non-polyposis colorectal cancer (HNPCC) is
a cancer susceptibility syndrome characterized by in-
creased risk for colorectal cancer (CRC). Genetic testing
for HNPCC can risk-stratify family members. Those
lacking inherited susceptibility can avoid costly and fre-
quent colonoscopic surveillance. OBJECTIVE: Evaluate
the cost-effectiveness of a genetic testing strategy for a
family member at risk for inheriting susceptibility to
HNPCC-related CRC. METHODS: A decision analytic
model simulated health and economic outcomes. A hypo-
thetical cohort of 20 year-old consultants from HNPCC
kindreds progressed through the model. We assumed that
surveillance prevents CRC, and that patients averaged a
life expectancy of 80 years. The genetic testing strategy
included relevant mutation analysis with and without
screening a family member’s tumor tissue for microsatel-
lite instability (MSI) and immunohistochemical (IHC)
staining for the MLH1 and MSH2 gene products. Pa-
tients testing negative for a familial mutation underwent
surveillance as recommended by the American Cancer
Society, and those positive as recommended by the Inter-
national Collaborative Group for high-risk patients.
Probability estimates were derived from a systematic re-
view of the MEDLINE and HEALTSTAR databases.
Cost estimates were derived from the Medicare 1999
Physician Fee Schedule—Area 18. Sensitivity analyses
were performed on all estimates. The outcome was cost-
per-strategy to prevent CRC. RESULTS: The genetic test-
ing strategy yielded an average savings of $869.73 per
patient. Its cost-effectiveness persisted over a wide range
of probability and cost variables. The genetic testing
strategy resulted in 67% fewer invasive, endoscopic pro-
cedures. CONCLUSION: Both costs and procedures for
CRC surveillance and prevention are substantially re-
duced for at-risk individuals from an HNPCC kindred
who participate in a strategy that begins with genetic
testing.
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Low Grade Non-Hodgkin’s Lymphoma (LGNHL) is an
indolent form of NHL with a median survival of four to
eleven years. This survival is dependent on the respon-
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siveness to therapy and the number of disease relapses.
After multiple relapses, this lymphoma becomes refrac-
tory to standard therapies. Thus the median survival is
dramatically shortened to 24 to 26 months. Relapsed, re-
fractory low-grade lymphoma (RRLGNHL) is a common
disease progression and the focus of multiple studies in
the search for more effective therapies. Rituximab is an
anti-CD20 immunotherapy approved for the treatment
of RRLGNHL. It is marginally more effective in refrac-
tory cases than salvage therapy, but has a less severe side
effect profile. OBJECTIVE: To estimate the cost-effec-
tiveness ratio of rituximab in the treatment of RRLGNHL.
METHODS: The study utilized a societal perspective
with a two-year time horizon and an annual discount
rate of 3%. Outcomes data and their probabilities were
abstracted from randomized controlled trials for ritux-
imab and DHAP in RRLGNHL patient populations. Di-
rect medical costs, drug costs and health-state related
utilities were abstracted from other studies, standard
Medicare reimbursement rates and the Red Book. An in-
cremental cost-effectiveness ratio (ICE) was used to esti-
mate the effectiveness of rituximab compared to DHAP.
RESULTS: The study found an ICE ratio of $58,166 per
quality adjusted life-year saved. The model was found to
be sensitive to the medication costs, medication response
rates and the cost of autologous bone marrow transplan-
tation. CONCLUSION: Based on the findings, rituximab
appears to be a marginally cost-effective alternative for
RRLGNHL. Relative drug costs and response rates must
be considered before a conclusion can be drawn for a
specific institution.
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The aim of the trial was to compare using cost-effective-
ness analysis two schemes of chemotherapy in advanced
breast cancer as the first line of therapy. METHODS: Pa-
tients were randomly assigned to chemotherapy. Arm A:
standard scheme CAF (30 pts), and arm B: scheme TAD
(23 pts), 126 cycles. Effect was estimated after finishing 6
cycles. Results: CR or PR was seen in 78% of cases
(TAD) and 60% of cases (CAF). Stabilization of the pro-
cess was 13% and 23%, progression of the process was
9% and 17% accordingly. The cost of each cycle is as
follows: hospital expenditures, cost of diagnostic and
laboratory tests and expenses on medicine. The cost of 6
cycles per patient is 9845 USD (TAD) and 2140 USD
(CAF). But high level of effectiveness of this treatment
provides repayment that is demonstrated in table:
As a result of cost-effectiveness analysis the analysis of
clinical decisions was made and decision tree was built.
The final calculation of cost/ effectiveness index showed
advantages of TAD scheme compared to CAF scheme:
So, the advantage of the preliminary data of TAD scheme
according to rational utilization makes 37% compared to
CAF scheme.
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Epoetin alpha (EPO) usage increased five-fold during the
past three years at The University of Texas MD Ander-
son Cancer Center (UTMDACC). EPO has been shown
to be safe and might be considered more effective than
treatment with red blood cell infusions for patients with
chemotherapy-induced anemia. OBJECTIVE: To deter-
mine patterns of EPO usage in cancer patients and to
evaluate physicians’ adherence to proposed clinical guide-
lines. METHODS: We conducted a retrospective data-
base analysis for all in-patient EPO prescriptions processed
at the UTMDACC from March 1 to April 30 of 1999.
Patients receiving EPO during this period were each fol-
lowed throughout the course of their drug therapy. Data
was extracted for these patients using a pharmacy elec-
tronic database. The following information was coded:
administration dates, hemoglobin (Hgb) levels, units ad-
ministered, drug (EPO) cost, disease category, age, gen-
der, ethnic group, and residence. Based on the Hgb levels,
the data was coded into two groups, within or outside
proposed EPO guidelines and analyzed to evaluate pat-
terns of drug use. RESULTS: A total of 119 patients
(52% males) were identified with an average age of 57
years (range 9–81 years). Total drug cost per month for
all patients was $100,643. Around 35% (n  41) of pa-
Scheme
Average value
(USD)
Value of effective ChT (USD)
Remission Progression
TAD 9845 7705 13843
CAF 2140 1214 4207
It is according
4 cycles 7–8 cycles
Effect
Cost/effectiveness index
TAD CAF
General effectiveness 0,0006 0,0040
Remission
0,003
0,0137
